CN108558883B - A kind of nucleic acid base compound or its pharmaceutically acceptable salt and its preparation method and application - Google Patents
A kind of nucleic acid base compound or its pharmaceutically acceptable salt and its preparation method and application Download PDFInfo
- Publication number
- CN108558883B CN108558883B CN201810493926.7A CN201810493926A CN108558883B CN 108558883 B CN108558883 B CN 108558883B CN 201810493926 A CN201810493926 A CN 201810493926A CN 108558883 B CN108558883 B CN 108558883B
- Authority
- CN
- China
- Prior art keywords
- structure shown
- formula
- compound
- base
- hydroxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 106
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 27
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 27
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 27
- 150000003839 salts Chemical class 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims description 25
- 108091005804 Peptidases Proteins 0.000 claims abstract description 19
- 239000004365 Protease Substances 0.000 claims abstract description 18
- 239000003112 inhibitor Substances 0.000 claims abstract description 17
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims abstract description 16
- 102100034343 Integrase Human genes 0.000 claims abstract 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract 3
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 claims description 84
- 150000001412 amines Chemical class 0.000 claims description 61
- 238000006243 chemical reaction Methods 0.000 claims description 54
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 47
- -1 amino, methoxyl group Chemical group 0.000 claims description 42
- 239000001257 hydrogen Substances 0.000 claims description 42
- 229910052739 hydrogen Inorganic materials 0.000 claims description 42
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 38
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 31
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 30
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 30
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 claims description 28
- 238000006482 condensation reaction Methods 0.000 claims description 23
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 150000002431 hydrogen Chemical class 0.000 claims description 20
- 239000003054 catalyst Substances 0.000 claims description 19
- 238000006467 substitution reaction Methods 0.000 claims description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 18
- 238000010511 deprotection reaction Methods 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- 230000000269 nucleophilic effect Effects 0.000 claims description 14
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 14
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical class N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 13
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 12
- 238000006722 reduction reaction Methods 0.000 claims description 11
- 125000003368 amide group Chemical group 0.000 claims description 10
- 150000003230 pyrimidines Chemical class 0.000 claims description 10
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 claims description 9
- 238000006073 displacement reaction Methods 0.000 claims description 9
- LAYPMCGIWDGYKX-UHFFFAOYSA-N trichloromethyl hydrogen carbonate Chemical class OC(=O)OC(Cl)(Cl)Cl LAYPMCGIWDGYKX-UHFFFAOYSA-N 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
- 239000005864 Sulphur Substances 0.000 claims description 7
- 230000009471 action Effects 0.000 claims description 7
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 claims description 7
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 239000011737 fluorine Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 6
- 230000003197 catalytic effect Effects 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 claims description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 5
- JBMBVWROWJGFMG-UHFFFAOYSA-N 2-chloro-7h-purine Chemical compound ClC1=NC=C2NC=NC2=N1 JBMBVWROWJGFMG-UHFFFAOYSA-N 0.000 claims description 4
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 4
- 150000002466 imines Chemical class 0.000 claims description 4
- UZQYFLWZKIMYKS-UHFFFAOYSA-N 8-methyl-7h-purine Chemical compound C1=NC=C2NC(C)=NC2=N1 UZQYFLWZKIMYKS-UHFFFAOYSA-N 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 29
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 10
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 abstract description 9
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 8
- 230000003013 cytotoxicity Effects 0.000 abstract description 8
- 229940124321 AIDS medicine Drugs 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 56
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 45
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 28
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 27
- 230000015572 biosynthetic process Effects 0.000 description 27
- 238000003786 synthesis reaction Methods 0.000 description 27
- 238000000034 method Methods 0.000 description 26
- 239000000243 solution Substances 0.000 description 24
- 239000003960 organic solvent Substances 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 21
- 229940125904 compound 1 Drugs 0.000 description 20
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- 102100034349 Integrase Human genes 0.000 description 17
- 239000012043 crude product Substances 0.000 description 17
- 239000012074 organic phase Substances 0.000 description 17
- 235000002639 sodium chloride Nutrition 0.000 description 17
- 239000007787 solid Substances 0.000 description 16
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 229960005107 darunavir Drugs 0.000 description 11
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 11
- 235000019419 proteases Nutrition 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000009833 condensation Methods 0.000 description 9
- 230000005494 condensation Effects 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 238000004809 thin layer chromatography Methods 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical group [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 229940125898 compound 5 Drugs 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 229940125782 compound 2 Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 238000005654 Michaelis-Arbuzov synthesis reaction Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 229940126214 compound 3 Drugs 0.000 description 6
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 5
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical group [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical group OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 4
- 229960003804 efavirenz Drugs 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000012805 post-processing Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 3
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- DTJVECUKADWGMO-UHFFFAOYSA-N 4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1 DTJVECUKADWGMO-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001112090 Pseudovirus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- 229960000523 zalcitabine Drugs 0.000 description 2
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- HBOMLICNUCNMMY-UHFFFAOYSA-N 1-[4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1OC(CO)C(N=[N+]=[N-])C1 HBOMLICNUCNMMY-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- WUKANDNCRFGEHC-UHFFFAOYSA-N 3-(dimethylamino)propyl-(ethyliminomethylidene)azanium;chloride;hydrochloride Chemical compound Cl.Cl.CCN=C=NCCCN(C)C WUKANDNCRFGEHC-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 1
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 description 1
- ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 235000010894 Artemisia argyi Nutrition 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- HFKJBCPRWWGPEY-BQBZGAKWSA-N L-arginyl-L-glutamic acid Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O HFKJBCPRWWGPEY-BQBZGAKWSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- ZXPSRPAUXQIYID-UHFFFAOYSA-N [N].[Na] Chemical compound [N].[Na] ZXPSRPAUXQIYID-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229940125777 fusion inhibitor Drugs 0.000 description 1
- 101150047047 gag-pol gene Proteins 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940124524 integrase inhibitor Drugs 0.000 description 1
- 239000002850 integrase inhibitor Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical class [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Medicinal Chemistry (AREA)
- AIDS & HIV (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a kind of nucleic acid base compound or its pharmaceutically acceptable salt, the compound or its pharmaceutically acceptable salt have the apparent activity for inhibiting hiv protease and/or reverse transcriptase;Toxicity research shows it with good druggability, shows that such compound has a good application prospect as anti-AIDS drug.Experimental data according to the embodiment is it is found that the compound of the present invention has inhibitory activity to HIV-1 protease and HIV-1 reverse transcriptase, and all has lower cytotoxicity.Nucleic acid base compound of the invention or its pharmaceutically acceptable salt are expected to become while inhibiting double target spot inhibitor of hiv protease and reverse transcriptase.
Description
Technical field
The present invention relates to nucleic acid base technical field more particularly to a kind of nucleic acid base compound or its is pharmaceutically acceptable
Salt and its preparation method and application.
Background technique
Acquired immunodeficiency syndrome (Acquired Immune Deficiency Syndrome, AIDS), also known as ends
Disease is grown, is that the mankind lead to immune lack because of infection immunity defective virus (Human Immunodeficiency Virus, HIV)
It falls into, and causes a series of syndrome of opportunistic infections and tumour.HIV is to be currently known differentiation, the highest virus of degree of variation,
According to serological reaction, gene order difference and Characteristics of Geographical Distribution, two hypotypes: HIV-1 and HIV-2 can be divided into.HIV-1 is
The pathogen for causing AIDS Global prevalence accounts for 95% absolute predominance on number of the infected;HIV-2 primary limitation is in Africa
Portion and western some areas, number of the infected are relatively fewer.
It goes through formally to be used for clinic AIDS medicine from Zidovudine (zidovudine, AZT) conduct in 1987 is first
Since object, existing more than 30 anti-AIDS drugs are applied to clinic at present, including a kind of entry inhibitors, 15 kinds of reverse transcriptions
Enzyme (RT) inhibitor, 10 kinds of protease (PR) inhibitor, a kind of integrase inhibitor, a kind of fusion inhibitor and 5 kinds of complexing agents
Deng.But prolonged application list target drug easily causes crossing drug resistant and serious toxic side effect.Chinese descendant in America's science in 1996
Family He great Yi is proposed " cocktail therapy " i.e. highly effective antiretroviral therapy (HAART), reduces what single drug was also easy to produce
Drug resistance inhibits the duplication of virus to the maximum extent, greatly improves the quality of life of patient.However this therapy dosage
Greatly, toxic side effect is strong, drug interaction is complicated, patient compliance is poor, and the severe situation faced above forces people constantly to visit
Rope finds novel inverase.
Multiple target point drug designs (multitarget-directed ligands, MT-DLs) due to its uniform pharmacokinetics
Property reduces drug interaction and improves the advantages such as therapeutic effect, it has also become the Disciplinary Frontiers of current medical design, for many
The treatment of difficult diseases brings new hope.Reverse transcriptase inhibitor and protease inhibitors are the head in " cocktail therapy "
Drug is selected, therefore the research of the bis- target spot inhibitor of HIV PR/RT has great importance.
HIV-1 reverse transcriptase (reverse transcriptase, RT) plays very in the reproduction process of inhibition of HIV
Important role is catalyzed RNA reverse transcription synthetic dsdna, and double-stranded DNA enters in nucleus under the action of integrase, and turns
Viral RNA is recorded, a part of host cell is become.Therefore, RT is the important target spot of inverase, while being also HIV earliest
Study target spot.
HIV-1 protease is the species specificity aspartyl protease encoded by HIV gene, and active form is two
The homodimer of identical peptide chain composition, every peptide chain are made of 99 amino acid residues, active site be located at two peptide chains it
Between.HIV-1 protease inhibitors is made infected thin by preventing shearing of the protease to viral gag gag-pol gene
Born of the same parents can only generate it is immature, do not have infective virus.Therefore, HIV-1PR is the important target spot for researching and developing inverase.
So far, there is not yet being able to suppress HIV-1 proteinase activity and reverse transcriptase activity and being applied to treatment Chinese mugwort
Grow the relevant report of the derivative of disease.
Summary of the invention
The purpose of the present invention is to provide a kind of active nucleic acid bases for being able to suppress HIV-1 protease and reverse transcriptase
Derivative or its pharmaceutically acceptable salt.
In order to achieve the above-mentioned object of the invention, the present invention the following technical schemes are provided:
The present invention provides a kind of nucleic acid base compound or its pharmaceutically acceptable salts, have structure shown in Formulas I:
In Formulas I, R1For amino, methoxyl group, nitro, aminomethyl or methylol;
X is-CH2,-O- ,-S- or-NH-;
When X is-CH2When, R Ra, Rb, Rc or Rd;
When X is-O- ,-S- or-NH-, R is Rc or Rd;
Wherein, R2For hydrogen, hydroxyl, amino or halogen;R3For hydrogen, hydroxyl, amino, halogen or methyl;R4For hydrogen or methyl;
R5For hydrogen, hydroxyl, amino or phosphate group;
When Z is nitrogen, R6For hydrogen, hydroxyl, amino or phosphate group;When Z is oxygen or sulphur, R6It is not present.
Preferably, the nucleic acid base compound includes 2- (the chloro- 9H- purine -9- base of 6-)-N- ((2S, 3R) -3- hydroxyl -
4- (N- isobutyl group -4- methoxyphenyl sulphonyl amido) -1- phenyl butane -2- base)-acetamide, 2- (8- methyl -9H- purine -
9- yl)-N- [(2S, 3R) -3- hydroxyl -4- (N- isobutyl group -4- methoxyphenyl sulphoxide imine base) -1- phenyl butyl -2- base] -
Acetamide, 2- (2,4- dioxo -2H-3,4- dihydro-pyrimidin -1- base)-N- ((2S, 3R) -3- hydroxyl -4- (N- isobutyl group -4- first
Phenyl sulfoamido) -1- phenyl butane -2- base)-acetamide, 2- (the fluoro- 2,4- dioxo -2H-3,4- dihydro-pyrimidin-of 5-
1- yl)-N- ((2S, 3R) -3- hydroxyl -4- (N- isobutyl group -4- methoxyphenyl sulphonyl amido) -1- phenyl butane -2- base)-second
Amide, ((2S, 5R) -5- (- 1 base of 1H-2- oxo -4- aminopyrimidine)-tetrahydrofuran -2- base) methyl N-((2S, 3R) -3- hydroxyl
Base -4- (N- isobutyl group -4- aminocarbonyl phenyl sulfoamido) -1- phenyl butane -2- base))-carbamate or N- ((2R, 3S) -
3- (2- (the fluoro- 2,4- dioxo -2H-3,4- dihydro-pyrimidin -2H-1- base of 5-) acetamido) -2- hydroxy-4-phenyl butyl-N-
Isobutyl group-P- (4- methoxyphenyl) phosphamic acid.
The present invention provides the preparation methods of the nucleic acid base compound described in above-mentioned technical proposal, comprising the following steps:
X is-CH in the compound of the structure shown in the Formulas I2, when R is Ra or Rb, by the change with structure shown in Formula II -1
It closes object and amine derivative carries out condensation reaction under the action of catalyst, obtain the compound with structure shown in Formulas I;
In Formula II -1, R is Ra or Rb, and the Ra isThe Rb isWherein,
R2For hydrogen, hydroxyl, amino or halogen;R3For hydrogen, hydroxyl, amino, halogen or methyl;R4For hydrogen or methyl;
X is-CH in the compound of the structure shown in the Formulas I2,-O- ,-S- or-NH-, R be when being Rc or Rd, will have Formula II-
Compound, carbonic acid trichloromethyl ester and the amine derivative of structure shown in 2 carry out condensation reaction under the action of catalyst, are had
The compound of structure shown in Formulas I;
Formula II -2 R-XH,
In Formula II -2, X is-CH2,-O- ,-S- or-NH-;R is Rc or Rd, and the Rc isThe Rd isWherein, R2For hydrogen, hydroxyl, amino or halogen, R3For hydrogen, hydroxyl, amino, halogen or methyl;R4For hydrogen
Or methyl;R5For hydrogen, hydroxyl, amino or phosphate group;When Z is nitrogen, R6For hydrogen, hydroxyl, amino or phosphate group;When Z is oxygen
Or when sulphur, R6It is not any atom or group;
The amine derivative has structure shown in formula III:
Preferably, the compound and amine derivative with structure shown in Formula II -1 is in carbodiimide hydrochloride, 1-
Condensation reaction is carried out under the catalytic action of hydroxybenzotriazole and 4-dimethylaminopyridine;
The compound and carbonic acid trichloromethyl ester and amine derivative with structure shown in Formula II -2 is in N, N- diisopropyl
Condensation reaction is carried out under the catalytic action of base ethamine.
Preferably, the preparation method of the compound with structure shown in Formula II -1, comprising the following steps:
Substituted pyrimidines base or substituted purin base and bromoacetic acid or bromoacetate are subjected to substitution reaction, replaced
Product;
The substitution product is hydrolyzed, the compound with structure shown in Formula II -1 is obtained;
The substituted pyrimidines base has structure shown in formula a:
The substituted purin base has structure shown in formula b:
Preferably, when in the amine derivative Y beWhen, the amine derivative has structure shown in formula III -1:
The preparation method of the amine derivative with structure shown in formula III -1, comprising the following steps:
[(S) -1- ((S)-ethylene oxide -2- base) -2- benzene ethylamino t-butyl formate] is carried out nucleophilic with isobutyl amine to take
Generation reaction, obtains (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate;
The R of (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate by described in and structure shown in formula d1
Substituted phenylsulfonyl chloride carries out nucleophilic substitution, obtains the intermediate of structure shown in formula c;
By the intermediate Deprotection of structure shown in the formula c, the amine derivative with structure shown in formula III -1 is obtained;
Preferably, when in the amine derivative Y beWhen, the amine derivative has structure shown in formula III -2:
The preparation method of the amine derivative with structure shown in formula III -2, comprising the following steps:
[(S) -1- ((S)-ethylene oxide -2- base) -2- benzene ethylamino t-butyl formate] is carried out nucleophilic with isobutyl amine to take
Generation reaction, obtains (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate;
The R of (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate by described in and structure shown in formula d1
Substituted phenylsulfonyl chloride carries out nucleophilic substitution, obtains the intermediate of structure shown in formula c;
The intermediate of structure shown in the formula c and Sodium azide are subjected to imidization, obtain the centre of structure shown in formula e
Body;
By the intermediate Deprotection of structure shown in the formula e, the amine derivative with structure shown in formula III -2 is obtained.
Preferably, when in the amine derivative Y beWhen, the amine derivative has structure shown in formula III -3:
The preparation method of the amine derivative with structure shown in formula III -3, comprising the following steps:
[(S) -1- ((S)-ethylene oxide -2- base) -2- benzene ethylamino t-butyl formate] is carried out nucleophilic with isobutyl amine to take
Generation reaction, obtains (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate;
By 4- substituted-phenyl phosphonyl dichloride, benzyl alcohol and (1S, the 2R) -1- benzyl -2- hydroxyl with structure shown in formula f
Base -3- (isobutyl amine) t-butyl carbamate carries out Arbuzov and reacts to obtain the intermediate of structure shown in formula g;
By the intermediate and H of structure shown in the formula g2Reduction reaction is carried out, the intermediate of structure shown in formula h is obtained;
By the intermediate Deprotection of structure shown in the formula h, the amine derivative with structure shown in formula III -3 is obtained.
The present invention provides nucleic acid base compounds described in above-mentioned technical proposal or its pharmaceutically acceptable salt to prepare
Application in hiv inhibitor, the hiv inhibitor is using hiv protease and reverse transcriptase as target spot.
Preferably, the dosage of the nucleic acid base compound or its pharmaceutically acceptable salt in hiv inhibitor is
0.01~100nM.
The present invention provides a kind of nucleic acid base compound or its pharmaceutically acceptable salt, the compound or its pharmaceutically
Acceptable salt has the apparent activity for inhibiting hiv protease and/or reverse transcriptase;Toxicity research shows it with good
Druggability shows that such compound has a good application prospect as anti-AIDS drug.Experimental data according to the embodiment
It is found that the compound of the present invention has inhibitory activity (table 1) to HIV-1 protease and HIV-1 reverse transcriptase, and all have
Lower cytotoxicity (table 2).Nucleic acid base compound of the invention or its pharmaceutically acceptable salt are expected to become while pressing down
Double target spot inhibitor of hiv protease and reverse transcriptase processed.
Detailed description of the invention
The compound of Fig. 1 Formulas I structure;
The synthetic route chart of Fig. 2 compound 1;
The synthetic route chart of Fig. 3 compound 2;
The synthetic route chart of Fig. 4 compound 3;
The synthetic route chart of Fig. 5 compound 4;
The synthetic route chart of Fig. 6 compound 5;
The synthetic route chart of Fig. 7 compound 6.
Specific embodiment
The present invention provides a kind of nucleic acid base compound or its pharmaceutically acceptable salts, have structure shown in Formulas I:
In Formulas I, R1For amino, methoxyl group, nitro, aminomethyl or methylol;
X is-CH2,-O- ,-S- or-NH-;
When X is-CH2When, R Ra, Rb, Rc or Rd;
When X is-O- ,-S- or-NH-, R is Rc or Rd;
Wherein, R2For hydrogen, hydroxyl, amino or halogen;R3For hydrogen, hydroxyl, amino, halogen or methyl;R4For hydrogen or methyl;
R5For hydrogen, hydroxyl, amino or phosphate group;
When Z is nitrogen, R6For hydrogen, hydroxyl, amino or phosphate group;When Z is oxygen or sulphur, R6It is not present.
In the present invention, the nucleic acid base compound preferably include 2- (the chloro- 9H- purine -9- base of 6-)-N- ((2S,
3R) -3- hydroxyl -4- (N- isobutyl group -4- methoxyphenyl sulphonyl amido) -1- phenyl butane -2- base)-acetamide, 2- (8- first
Base -9H- purine -9- base)-N- [(2S, 3R) -3- hydroxyl -4- (N- isobutyl group -4- methoxyphenyl sulphoxide imine base) -1- phenyl
Butyl -2- base]-acetamide, 2- (2,4- dioxo -2H-3,4- dihydro-pyrimidin -1- base)-N- ((2S, 3R) -3- hydroxyl -4- (N-
Isobutyl group -4- methoxyphenyl sulphonyl amido) -1- phenyl butane -2- base)-acetamide, 2- (the fluoro- 2,4- dioxo -2H-3 of 5-,
4- dihydro-pyrimidin -1- base)-N- ((2S, 3R) -3- hydroxyl -4- (N- isobutyl group -4- methoxyphenyl sulphonyl amido) -1- phenyl fourth
Alkane -2- base)-acetamide, ((2S, 5R) -5- (- 1 base of 1H-2- oxo -4- aminopyrimidine)-tetrahydrofuran -2- base) methyl N -
((2S, 3R) -3- hydroxyl -4- (N- isobutyl group -4- aminocarbonyl phenyl sulfoamido) -1- phenyl butane -2- base))-carbamate
Or N- ((2R, 3S) -3- (2- (the fluoro- 2,4- dioxo -2H-3,4- dihydro-pyrimidin -2H-1- base of 5-) acetamido) -2- hydroxyl -
4- phenyl butyl-N- isobutyl group-P- (4- methoxyphenyl) phosphamic acid.
The present invention provides the preparation methods of the nucleic acid base compound described in above-mentioned technical proposal, comprising the following steps:
X is-CH in the compound of the structure shown in the Formulas I2, when R is Ra or Rb, by the change with structure shown in Formula II -1
It closes object and amine derivative carries out condensation reaction under the action of catalyst, obtain the compound with structure shown in Formulas I;
In Formula II -1, R is Ra or Rb, and the Ra isThe Rb isWherein,
R2For hydrogen, hydroxyl, amino or halogen;R3For hydrogen, hydroxyl, amino, halogen or methyl;R4For hydrogen or methyl;
X is-CH in the compound of the structure shown in the Formulas I2,-O- ,-S- or-NH-, R be when being Rc or Rd, will have Formula II-
Compound, carbonic acid trichloromethyl ester and the amine derivative of structure shown in 2 carry out condensation reaction under the action of catalyst, are had
The compound of structure shown in Formulas I;
Formula II -2 R-XH,
In Formula II -2, X is-CH2,-O- ,-S- or-NH-;R is Rc or Rd, and the Rc isThe Rd isWherein, R2For hydrogen, hydroxyl, amino or halogen, R3For hydrogen, hydroxyl, amino, halogen or methyl;R4For
Hydrogen or methyl;R5For hydrogen, hydroxyl, amino or phosphate group;When Z is nitrogen, R6For hydrogen, hydroxyl, amino or phosphate group;When Z is
When oxygen or sulphur, R6It is not any atom or group;
The amine derivative has structure shown in formula III:
In the present invention, the compound and amine derivative with structure shown in Formula II -1 is preferably in carbodiimides salt
Condensation reaction is carried out under the catalytic action of hydrochlorate, I-hydroxybenzotriazole and 4-dimethylaminopyridine, is obtained with knot shown in Formulas I
The compound of structure, reaction process are as follows:
In the present invention, the compound with structure shown in Formula II -1, amine derivative, carbodiimide hydrochloride,
The molar ratio of I-hydroxybenzotriazole and 4-dimethylaminopyridine is preferably 1:(1.0~1.1): (1.4~1.6): (1.0~
1.2): (0.19~0.21), more preferably 1:1.05:1.5:1.1:0.2.In the present invention, the carbodiimide hydrochloride
Preferably 1- ethyl-(3- dimethylaminopropyl) carbodiimide hydrochloride.In the present invention, the condensation reaction preferably exists
It is carried out under the conditions of organic solvent is existing;The present invention does not have the type of the organic solvent special restriction, using ability
The organic solvent that condensation reaction can be made to go on smoothly known to field technique personnel, it is specific such as dimethylformamide (DMF).
In the present invention, the condensation reaction preferably includes following steps:
Compound, amine derivative and DMF with structure shown in Formula II -1 are mixed, mixed under condition of ice bath to gained
Carbodiimide hydrochloride and I-hydroxybenzotriazole are added in solution, carries out first 0.5~1.5h of condensation reaction at room temperature;
Then 4-dimethylaminopyridine is added in resulting material, carries out second 1.5~2.5h of condensation reaction at room temperature.
After completing the condensation reaction, the present invention preferably post-processes gained condensation material, obtains with shown in Formulas I
The compound of structure.In the present invention, the post-processing preferably includes following steps:
It carries out gained condensation material that removal DMF is concentrated under reduced pressure, residue be mixed with water, using ethyl acetate to gained
Mixture is extracted, and gained organic phase is dry with anhydrous sodium sulfate, and the organic phase after drying is concentrated to give crude product,
The crude product is prepared thin-layer chromatography through silica gel to isolate and purify, obtains the compound with structure shown in Formulas I.
In the present invention, the preparation method of the compound with structure shown in Formula II -1, preferably includes following steps:
Substituted pyrimidines base or substituted purin base and bromoacetic acid or bromoacetate are subjected to substitution reaction, replaced
Product;
The substitution product is hydrolyzed, the compound with structure shown in Formula II -1 is obtained;
The substituted pyrimidines base has structure shown in formula a:
The substituted purin base has structure shown in formula b:
Substituted pyrimidines base or substituted purin base and bromoacetic acid or bromoacetate preferably replace anti-by the present invention
It answers, obtains substitution product.In the present invention, the substituted pyrimidines base with structure shown in formula a and there is structure shown in formula b
Substituted purin base be preferably commercial product.In the present invention, the substituted pyrimidines base or substituted purin base and bromine second
The molar ratio of acid or bromoacetate preferably stands alone as 10:(10~12), more preferably 10:11.In the present invention, the substitution
Reaction preferably existing for the catalyst and organic solvent under the conditions of carry out;Kind of the present invention for the catalyst and organic solvent
Class does not have special restriction, using the catalyst well known to those skilled in the art that substitution reaction can be made to go on smoothly and organic
Solvent, it is specific if catalyst is sodium hydride, organic solvent DMF.
In the present invention, the substitution reaction preferably includes following steps:
Substituted pyrimidines base or substituted purin base are mixed with DMF, under condition of ice bath, sodium hydride is added drop-wise to gained
In mixture, displacement 0.5~1.5h of reaction is carried out at room temperature, bromoacetic acid or bromoacetate are added drop-wise to gained and replace reactant
In material, 0.5~1.5h of substitution reaction is carried out at room temperature.
After completing the substitution reaction, gained is preferably replaced material to post-process by the present invention, obtains substitution product.?
In the present invention, the post-processing preferably includes following steps:
Replace material to mix with water gained, extracted with ethyl acetate, gained organic phase is done with anhydrous sodium sulfate
It is dry, the organic phase after drying is concentrated to give crude product, the crude product is prepared into thin-layer chromatography through silica gel and is isolated and purified,
Obtain substitution product.
After obtaining substitution product, the present invention preferably hydrolyzes the substitution product, obtains having structure shown in Formula II -1
Compound.In the present invention, the hydrolysis preferably existing for the sodium hydroxide solution under the conditions of carry out;The sodium hydroxide solution
Concentration be preferably 3mol/L;The molar ratio of the substitution product and sodium hydroxide is preferably 1:3.In the present invention, described
The temperature of hydrolysis is preferably 25~35 DEG C, specifically can be room temperature;The time of the hydrolysis is preferably 0.5~
1.5h, more preferably 1h.
After completing the hydrolysis, the present invention preferably post-processes gained hydrolysis material, obtains with Formula II -1
The compound of shown structure.In the present invention, the post-processing preferably includes following steps:
Using hydrochloric acid solution by gained hydrolysis material pH value be adjusted to 3.5~4.5, under condition of ice bath stir 25~
Solid is precipitated in 35min, filters, and filter cake is washed with water, dries, and obtains the compound with structure shown in Formula II -1.
In the present invention, when in the amine derivative Y beWhen, the amine derivative has knot shown in formula III -1
Structure:
The preparation method of the amine derivative with structure shown in formula III -1, preferably includes following steps:
[(S) -1- ((S)-ethylene oxide -2- base) -2- benzene ethylamino t-butyl formate] is carried out nucleophilic with isobutyl amine to take
Generation reaction, obtains (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate;
The R of (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate by described in and structure shown in formula d1
Substituted phenylsulfonyl chloride carries out nucleophilic substitution, obtains the intermediate of structure shown in formula c;
By the intermediate Deprotection of structure shown in the formula c, the amine derivative with structure shown in formula III -1 is obtained;
The present invention is preferably by [(S) -1- ((S)-ethylene oxide -2- base) -2- benzene ethylamino t-butyl formate] and isobutyl amine
Nucleophilic substitution is carried out, (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate is obtained.In the present invention
In, 3 [(S) -1- ((S)-ethylene oxide -2- base) -2- benzene ethylamino t-butyl formates] are preferred with the molar ratio of isobutyl amine
For (73~78): (187~192), more preferably (75~76): (189~190), most preferably 76:189.In the present invention,
3 [(S) -1- ((S)-ethylene oxide -2- base) -2- benzene ethylamino t-butyl formates] are preferably commercial product, specifically may be used
To derive from lark prestige Science and Technology Ltd..In the present invention, the nucleophilic displacement of fluorine preferably existing for the organic solvent under the conditions of
It carries out, the organic solvent is preferably acetonitrile.In the present invention, the temperature of the nucleophilic substitution is preferably 75~85 DEG C,
More preferably 80 DEG C;The time of reaction is preferably 4.5~5.5h, more preferably 5h.After completing the nucleophilic substitution, this hair
It is bright that preferably gained nucleophilic displacement of fluorine material is successively cooled down, is concentrated and recrystallized, obtain (1S, 2R) -1- benzyl -2- hydroxyl -
3- (isobutyl amine) t-butyl carbamate.In the present invention, recrystallization reagent used by the recrystallization is preferably acetic acid second
Ester and n-hexane;The volume ratio of ethyl acetate and n-hexane is preferably 1:(8~10 in the recrystallization reagent), more preferably 1:
9。
After obtaining (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate, the present invention preferably will be described
The R of (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate and structure shown in formula d1Substituted phenylsulfonyl chloride into
Row nucleophilic substitution obtains the intermediate of structure shown in formula c.In the present invention, described (1S, the 2R) -1- benzyl -2- hydroxyl -
3- (isobutyl amine) t-butyl carbamate and N, N- diisopropylethylamine, 4-dimethylaminopyridine and R1Substituted phenylsulfonyl chloride rubs
That ratio preferably 14~15:16~17:1~2:16~17, more preferably 14.86mmol:16.34mmol:1.49mmol:
16.34mmol.In the present invention, the nucleophilic substitution preferably existing for the organic solvent and catalyst under the conditions of carry out,
The organic solvent is preferably tetrahydrofuran and THF, and the catalyst is preferably n,N-diisopropylethylamine and 4- dimethylamino
Pyridine.The present invention is preferably first mixed by (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate and tetrahydrofuran
It closes, n,N-diisopropylethylamine, 4-dimethylaminopyridine, R is then added under condition of ice bath1Substituted phenylsulfonyl chloride and THF, into
Row nucleophilic substitution.In the present invention, the temperature of the nucleophilic substitution is preferably 0 DEG C of ice bath, and the nucleophilic displacement of fluorine is anti-
The time answered preferably 0.2~1h, more preferably 0.5h.The present invention preferably passes through TLC and detects the extent of reaction.The nucleophilic to be done
After substitution reaction, gained nucleophilic displacement of fluorine material is preferably concentrated under reduced pressure and removes THF by the present invention, then adopts and is extracted with ethyl acetate,
Extraction gained organic phase is concentrated, by concentration gained crude product through flash column purification, obtains the intermediate of structure shown in formula c.
In the present invention, eluant, eluent used by the flash column purification is preferably ethyl acetate and n-hexane, second in the eluant, eluent
The volume ratio of acetoacetic ester and n-hexane is preferably 1:5.
After obtaining the intermediate of structure shown in formula c, the intermediate of structure shown in the formula c is preferably deprotected by the present invention
Base obtains the amine derivative with structure shown in formula III -1.In the present invention, the Deprotection preferably in organic solvent and
It is carried out under the conditions of catalyst is existing, the organic solvent is preferably CH2Cl2, the catalyst is preferably trifluoroacetic acid.At this
In invention, the amount and CH of the substance of the intermediate of structure shown in the formula c2Cl2Volume ratio with trifluoroacetic acid is preferably 8~
10mmol:9~11mL:9~11mL, more preferably 9.87mmol:10mL:10mL.In the present invention, the deprotection reaction
Temperature be preferably 25~35 DEG C, be specifically as follows room temperature;The time of the deprotection reaction is preferably 2~4h, more preferably
For 3h.After completing the deprotection reaction, then it is super that saturated sodium bicarbonate solution is added in the preferably first concentration of reaction solution of the present invention
Solid is precipitated in sound, stirring, filters, and will filter products therefrom and carries out column chromatography for separation, obtains having structure shown in formula III -1
Amine derivative.In the present invention, eluant, eluent used by the column chromatography for separation is preferably CH2Cl2And MeOH, the eluant, eluent
Middle CH2Cl2Volume ratio with MeOH is preferably 10:1.
In the present invention, when in the amine derivative Y beWhen, the amine derivative has knot shown in formula III -2
Structure:
The preparation method of the amine derivative with structure shown in formula III -2, preferably includes following steps:
3 [(S) -1- ((S)-ethylene oxide -2- base) -2- benzene ethylamino t-butyl formates] are carried out nucleophilic with isobutyl amine to take
Generation reaction, obtains (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate;
The R of (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate by described in and structure shown in formula d1
Substituted phenylsulfonyl chloride carries out nucleophilic substitution, obtains the intermediate of structure shown in formula c;
The intermediate of structure shown in the formula c and Sodium azide are subjected to imidization, obtain the centre of structure shown in formula e
Body;
By the intermediate Deprotection of structure shown in the formula e, the amine derivative with structure shown in formula III -2 is obtained;
In the present invention, the specific preparation method of the intermediate of structure shown in the formula c is same as mentioned above, herein not
It repeats again.
After obtaining the intermediate of structure shown in formula c, the present invention is preferably by the intermediate and Sodium azide of structure shown in the formula c
Imidization is carried out, the intermediate of structure shown in formula e is obtained.In the present invention, the intermediate of structure shown in the formula c and folded
The molar ratio of nitrogen sodium is preferably 6~7:6~7, more preferably 6.30:6.90.In the present invention, the imidization preferably exists
It is carried out under the conditions of organic solvent and catalyst are existing, the organic solvent is preferably anhydrous chloroform, and the catalyst is excellent
It is selected as the concentrated sulfuric acid.In the imidization, the present invention is preferably first by the intermediate of structure shown in formula c and anhydrous chloroform
Mixing, Sodium azide is then added under protection of argon gas, the concentrated sulfuric acid then is added dropwise under the conditions of 0 DEG C of ice bath.The present invention preferably exists
The process that the concentrated sulfuric acid is added dropwise is completed in 5min.In the present invention, the temperature of the imidization is preferably 40~50 DEG C, more excellent
It is selected as 45 DEG C;The time of the imidization is preferably 10~12h.Present invention preferably employs TIC to monitor reaction process.To complete
After the imidization, present invention preferably uses chloroforms to extract gained reactant material, then uses saturated common salt water washing
Organic phase is concentrated in organic phase after drying, is purified by silica gel column chromatography to enriched product, obtains the intermediate of structure shown in formula e.
In the present invention, eluant, eluent used by the silica gel column chromatography purifies is preferably ethyl acetate and methanol, in the eluant, eluent
The volume ratio of ethyl acetate and methanol is preferably 30:1.
After obtaining the intermediate of structure shown in formula e, the present invention obtains the intermediate Deprotection of structure shown in the formula e
To the amine derivative with structure shown in formula III -2.The intermediate of structure shown in formula e is carried out the specific of Deprotection by the present invention
Method is identical as the above-mentioned method of intermediate Deprotection by structure shown in formula c, and details are not described herein.
In the present invention, when in the amine derivative Y beWhen, the amine derivative has shown in formula III -3
Structure:
The preparation method of the amine derivative with structure shown in formula III -3, preferably includes following steps:
[(S) -1- ((S)-ethylene oxide -2- base) -2- benzene ethylamino t-butyl formate] is carried out nucleophilic with isobutyl amine to take
Generation reaction, obtains (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate;
By 4- substituted-phenyl phosphonyl dichloride, benzyl alcohol and (1S, the 2R) -1- benzyl -2- hydroxyl with structure shown in formula f
Base -3- (isobutyl amine) t-butyl carbamate carries out Arbuzov reaction, obtains the intermediate of structure shown in formula g;
By the intermediate and H of structure shown in the formula g2Reduction reaction is carried out, the intermediate of structure shown in formula h is obtained;
By the intermediate Deprotection of structure shown in the formula h, the amine derivative with structure shown in formula III -3 is obtained;
The present invention carries out [(S) -1- ((S)-ethylene oxide -2- base) -2- benzene ethylamino t-butyl formate] and isobutyl amine
Nucleophilic substitution, obtain the specific method of (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate with it is upper
It is identical to state content, details are not described herein.
After obtaining (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate, the present invention will preferably have
4- substituted-phenyl phosphonyl dichloride, benzyl alcohol and (1S, the 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) of structure shown in formula f
T-butyl carbamate carries out Arbuzov reaction, obtains the intermediate of structure shown in formula g.In the present invention, described that there is formula f
The 4- substituted-phenyl phosphonyl dichloride and (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate of shown structure
The amount of substance and the volume ratio of benzyl alcohol be preferably 4~5mol:3~4mL:3~4mol, more preferably 4.16:3.78:
3.78.In the present invention, Arbuzov reaction preferably existing for the organic solvent and catalyst under the conditions of carry out;It is described to have
Solvent is preferably benzene, and the catalyst is selected as n,N-diisopropylethylamine (DIEA) and 1-H- tetrazole.In the present invention, institute
It states Arbuzov reaction and preferably includes following steps:
4- substituted-phenyl phosphonyl dichloride, 1-H- tetrazole with structure shown in formula f are dissolved in benzene, under condition of ice bath to
Successively be added dropwise benzyl alcohol, n,N-diisopropylethylamine (DIEA) in gained mixed solution, carry out the first ice bath reaction 25~
35min;After completing the reaction of the first ice bath, first 2~3h of room temperature reaction is carried out at room temperature;After completing the first room temperature reaction,
(1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) carbamic acid uncle is sequentially added under condition of ice bath into gained reactant material
Butyl ester and DIEA carry out the second ice bath and react 25~35min;After completing the reaction of the second ice bath, the second room temperature is carried out at room temperature
React 3~4h.
After completing Arbuzov reaction, present invention preferably employs reversed-phase column chromatography to gained Arbuzov reaction mass into
Row isolates and purifies, and obtains the intermediate of structure shown in formula g.In the present invention, the mobile phase of the reversed-phase column chromatography is preferably second
The mixed liquor of alcohol and water, the volume ratio of ethyl alcohol and water is preferably 5:1 in the mobile phase.
After obtaining the intermediate of structure shown in formula g, the present invention is preferably by the intermediate and H of structure shown in the formula g2It carries out
Reduction reaction obtains the intermediate of structure shown in formula h.In the present invention, the reduction reaction is preferably in organic solvent and catalysis
It is carried out under the conditions of agent is existing, the organic solvent is preferably tetrahydrofuran, and the catalyst is preferably Pd/C.In the reduction
In reaction, the present invention is preferably under protection of argon gas by the intermediate of structure shown in formula g and tetrahydrofuran, Pd/C, K2CO3It is mixed with water
It closes, then replaces the argon gas using hydrogen, carry out the reduction reaction at room temperature.In the present invention, the reduction reaction
Time be preferably 3~5h, more preferably 4h, the temperature of the reduction reaction is preferably 25~35 DEG C, specifically can be room
Temperature.After completing the reduction reaction, present invention preferably uses miillpore filters to be filtered reaction solution obtained by reduction reaction, in ice
Under the conditions of bath, the pH value of gained filtrate is adjusted to 5.0 using hydrochloric acid, is then extracted using ethyl acetate, with anhydrous sulphur
The dry organic phase of sour sodium, is concentrated organic phase, obtains the intermediate of structure shown in formula h.
After obtaining the intermediate of structure shown in formula h, the intermediate of structure shown in the formula h is preferably deprotected by the present invention
Base obtains the amine derivative with structure shown in formula III -3.The intermediate of structure shown in formula h is carried out Deprotection by the present invention
Specific method it is identical as the above-mentioned method of intermediate Deprotection by structure shown in formula c, details are not described herein.
In the present invention, the compound and carbonic acid trichloromethyl ester and amine derivative with structure shown in Formula II -2 are excellent
It is selected under the catalytic action of n,N-diisopropylethylamine and carries out condensation reaction, obtain the compound with structure shown in Formulas I, react
Process is as follows:
In the present invention, compound, carbonic acid trichloromethyl ester, amine derivative and the N with structure shown in Formula II -2,
The molar ratio of N- diisopropylethylamine is preferably 0.5:(0.45~0.55): (0.5~0.6): (0.5~0.6), more preferably
0.5:0.5:0.55:0.55.In the present invention, the condensation reaction preferably existing for the organic solvent under the conditions of carry out;It is described
Organic solvent is preferably anhydrous organic solvent.The present invention does not have the type of the organic solvent special restriction, using this
The organic solvent that condensation reaction can be made to go on smoothly known to the technical staff of field, it is specific such as methylene chloride and/or four
Hydrogen furans.In the present invention, the condensation reaction preferably includes following steps:
Carbonic acid trichloromethyl ester is mixed with methylene chloride under the conditions of ice bath, nitrogen protection, obtains the first mixed solution;
Compound with structure shown in Formula II -2, n,N-diisopropylethylamine are mixed with tetrahydrofuran, the second mixed solution is obtained;
Second mixed solution is added drop-wise in first mixed solution under condition of ice bath, it is anti-to carry out the first condensation at room temperature
25~35min is answered, the first condensation material is obtained;
Amine derivative is mixed with methylene chloride, n,N-diisopropylethylamine is added drop-wise in gained mixed solution, in room
Temperature is lower to carry out second 4~6min of condensation reaction, obtains the second condensation material;
First condensation material is mixed with the second condensation material, carries out 0.5~1.5h of condensation reaction at room temperature.
After completing the condensation reaction, the present invention preferably post-processes gained condensation material, obtains with shown in Formulas I
The compound of structure.In the present invention, the post-processing preferably includes following steps:
Gained condensation material is mixed with methylene chloride, is washed with saturated ammonium chloride solution, gained organic phase is used
Anhydrous sodium sulfate is dry, and the organic phase after drying is concentrated to give crude product, the crude product is prepared thin-layer chromatography through silica gel
It is isolated and purified, obtains the compound with structure shown in Formulas I.In the present invention, the method for the thin-layer chromatography with it is above-mentioned
Scheme is identical, and details are not described herein.
In the present invention, the compound with structure shown in Formula II -2 is preferably commercially available substituted nucleosides or deoxidation core
Glycosides.
In the present invention, the preparation method of the amine derivative is identical as above scheme, and details are not described herein.
The present invention provides nucleic acid base compounds described in above-mentioned technical proposal or its pharmaceutically acceptable salt to prepare
Application in hiv inhibitor, the hiv inhibitor is using hiv protease and reverse transcriptase as target spot.
Preferably, the dosage of the nucleic acid base compound or its pharmaceutically acceptable salt in hiv inhibitor is
0.01-100nM。
Nucleic acid base compound provided by the invention or its pharmaceutically acceptable salt are carried out below with reference to embodiment detailed
Thin explanation, but they cannot be interpreted as limiting the scope of the present invention.
6-chloropurine (0.62g, 4mmol) and Anhydrous potassium carbonate (1.66g, 12mmol) are added in 10mL eggplant-shape bottle,
Anhydrous solvent n,N-Dimethylformamide (DMF) 2mL is added, room temperature is vigorously stirred reaction 1h under nitrogen protection;By bromoacetic acid
(0.64g, 4.6mmol) is dissolved in anhydrous solvent n,N-Dimethylformamide (DMF) 1mL, is slowly dropped in reaction solution, is added
It finishes, continues to be stirred at room temperature reaction overnight.5mL distilled water is added into reaction solution, with diatomite filtering solution, washing is obtained
Yellow clarified solution body adjusts pH to 3.0 with 4M HCl, stirs 10min under ice bath, stand, filter under ice bath stirring state,
Filter cake is washed with a small amount, dry, obtains target product yellow greenish powder solid i.e. intermediate 1 (0.37g, 43.4%).Intermediate 1
LC-MS (ESI, M+H+)m/z 213.4。
By (S) -1- ((S)-ethylene oxide -2- base) -2- benzene ethylamino t-butyl formate (20.0g, 75.94mmol), second
Nitrile 80mL and isobutyl amine (19.02mL, 189.46mmol) are added in 200mL eggplant-shape bottle, and 80 DEG C of mixture are stirred 5 hours.Reaction
After reaction solution be cooled to room temperature, be concentrated under reduced pressure remove solvent.Crude product obtains after being recrystallized with ethyl acetate/n-hexane (1:9)
White object product (21.2g, 83%), the white object product are intermediate b1, LC-MS (ESI, M+H+)m/z 337.2。
Intermediate b1 (5.0g, 14.86mmol), tetrahydrofuran (THF) (40mL) are added in 250mL eggplant-shape bottle, ice bath
Under be slowly added to n,N-diisopropylethylamine (DIEA) (3.68mL, 16.34mmol) and 4-dimethylaminopyridine (DMAP)
(0.18g, 1.49mmol), is then added 4- Methoxybenzenesulfonyl chloride (3.38g, 16.34mmol) and the mixing of THF (10mL) is molten
Liquid.It is stirred 0.5 hour under ice bath and moves to room temperature.TLC detection is concentrated under reduced pressure after completion of the reaction removes THF, ethyl acetate extraction (30
× 3mL), organic phase concentration.Crude product through flash column purification ethyl acetate-hexane (1:5) target product white solid be in
LC-MS (ESI, M+H+) m/z 507.0 of mesosome b2 (6.14g, 82%), intermediate b2.
Intermediate b2 (5.0g, 9.87mmol) is added in 100mL eggplant-shape bottle, CH is added at room temperature2Cl2(10mL) and three
Fluoroacetic acid (10mL).It finishes, reacts at room temperature 3h.Concentration of reaction solution after completion of the reaction, and 200mL saturated sodium bicarbonate solution is added
Ultrasound, stirring, there is solid precipitation, filter to obtain crude product, and column chromatographs CH2Cl2- MeOH (10:1) target product white solid be in
Mesosome B1a (2.71g, 68%).LC-MS (ESI, M+H+) m/z 407.3 of intermediate B 1a.
Intermediate 1 (0.21g, 1mmol), intermediate B 1a (0.43g, 1.05mmol) are added in 10mL eggplant-shape bottle, are added
2mL anhydrous DMF, is placed in ice bath, is slowly added to 1- ethyl-(3- dimethylaminopropyl) carbodiimide hydrochloride hydrochloride
(EDCHCl) (0.29g, 1.5mmol), I-hydroxybenzotriazole (HOBt) (0.15g, 1.1mmol), finishes and is transferred to room temperature
It is stirred to react 1h, is added DMAP (0.024g, 0.2mmol), continues to be stirred to react 2h.DMF is concentrated under reduced pressure after completion of the reaction, remains
6mL water is added in object, is extracted with ethyl acetate (6 × 3mL), and organic phase is dry with anhydrous sodium sulfate, is concentrated to give crude product.Crude product is through silicon
Glue prepare thin-layer chromatography isolated and purified (solvent be ethyl acetate and methanol, by volume, ethyl acetate: methanol=8:
1) white powder solid (0.54g, 89.3%) to get to compound 1:2- (the chloro- 9H- purine -9- base of 6-)-N- ((2S,
3R) -3- hydroxyl -4- (N- isobutyl group -4- methoxyphenyl sulphonyl amido) -1- phenyl butane -2- base)-acetamide.
The synthetic route of compound 1 is shown in Fig. 2, and the analysis result of compound 1 is as follows: LC-MS (ESI, M+H+)m/z
601.7。1H NMR(400MHz,CDCl3)δ7.81(s,1H),7.62(s,1H),7.18-7.12(m,7H),7.01(brs,
2H),4.50(m,2H),4.25-4.23(m,1H),4.06(m.1H),3.90(s,3H),3.37(m,2H),3.04-2.88(m,
4H),1.92(m,1H),0.82(s,6H).13CNMR(101MHz,CDCl3)δ174.2,165.3,162.8,153.6,147.4,
138.1,137.0,130.3,129.5,128.3,127.0,114.3,71.6,57.5,55.7,54.6,47.6,34.5,26.8,
20.0。
8- methyl purine (1.34g, 10mmol) is added in 50mL eggplant-shape bottle, 10mL anhydrous DMF is added, is placed in ice bath
In, sodium hydride (0.44g, 11mmol) is slowly added portionwise, finishes and is transferred to room temperature and carries out reaction 1h, bromoacetic acid second is slowly added dropwise
Ester (1.84g, 11mmol), the reaction was continued 1h.Reaction is terminated, 10mL water is added, is extracted with ethyl acetate (15 × 3mL), it is organic
It is mutually dry with anhydrous sodium sulfate, it is concentrated to give yellow oily crude product.Through flash column purification, (eluant, eluent used is ethyl acetate to crude product
And hexane, by volume, ethyl acetate: hexane=1:2) obtain colorless needle crystals, that is, intermediate 2 (1.53g, 69.6%).It is intermediate
LC-MS (ESI, the M+H of body 2+)m/z 221.4。
NaOH (0.65g, 16.2mmol) is dissolved in 5mL water, is added to containing intermediate 2 (1.19g, 5.4mmol)
In 100mL eggplant-shape bottle, be stirred at room temperature reaction 1h, eggplant-shape bottle is placed in ice bath, under stirring with 4M HCl adjust pH to
4.0,30min is stirred under ice bath, a large amount of solids are precipitated, is stood, and is filtered, filter cake is washed with water, and it is dry, obtain target product white powder
Last solid, that is, intermediate 3 (0.58g, 56.3%).LC-MS (ESI, the M-H of intermediate 3-)m/z 191.4。
Intermediate b2 (3.19g, 6.30mmol) is added in the dry there-necked flask of 50mL, the anhydrous chloroform of 8mL is added,
It stirs evenly, is slowly added to Sodium azide (0.45g, 6.90mmol) under protection of argon gas, reaction flask is placed in ice bath, at 0 DEG C
It is lower to be slowly added dropwise with dropping funel into the 1.53mL concentrated sulfuric acid, it is added dropwise in 5min.Then reaction flask is transferred to 45 DEG C of conditions
Under be stirred to react overnight.TIC monitors reaction process, and reaction is quenched with water, and chloroform extracts (25 × 3mL), merges organic phase, uses
20mL saturated common salt water washing, dry, organic phase concentration.Crude product is purified by silica gel column chromatography acetate-methanol (30:1) and obtains
Target product white solid, that is, intermediate b3 (2.16g, 68%), LC-MS (ESI, M+H+) m/z 506.4 of intermediate b3.
Referring to the synthesis of the intermediate B 1a of embodiment 1, difference, which is only that, replaces intermediate b2 for the synthesis of intermediate B 2a
For equimolar intermediate b3, intermediate B 2a, yield 54.3%, LC-MS (ESI, M+H+) m/z of intermediate B 2a are obtained
406.3。
The synthesis of synthesis reference 1 compound 1 of embodiment of compound 2, the difference with the synthesis of compound 1 are only that by
Mesosome 1 replaces with equimolar intermediate 3, and B1a is replaced with equimolar B2a, and obtaining compound 2:2-, (8- methyl -9H- is fast
Purine -9- base)-N- [(2S, 3R) -3- hydroxyl -4- (N- isobutyl group -4- methoxyphenyl sulphoxide imine base) -1- phenyl butyl -2-
Base]-acetamide, yield 68.7%.
The synthetic route of compound 2 is shown in Fig. 3, and the analysis result of compound 2 is as follows: LC-MS (ESI, M+H+)m/z
583.7。1H NMR (600MHz, Acetone) δ 7.84 (s, 1H), 7.73 (d, J=8.8Hz, 2H), 7.63 (s, 1H), 7.26-
7.24 (m, 2H), 7.21-7.18 (m, 3H), 7.03 (d, J=8.8Hz, 2H), 4.04 (td, J=9.2,4.8Hz, 1H), 3.84
(s, 3H), 3.79 (m, 1H), 3.24 (dd, J=15.0,3.3Hz, 1H), 3.01 (ddd, J=23.4,14.4,6.0Hz, 2H),
2.91-2.86 (m, 2H), 2.67 (dd, J=13.8,10.6Hz, 1H), 1.92-1.88 (m, 1H), 0.86 (d, J=6.6Hz,
6H), 0.84 (d, J=6.6Hz, 6H) .13C NMR (151MHz, Acetone) δ 166.8,163.7,157.3,149.5,
145.9,141.3,139.4,132.0,130.2,130.0129.5,129.0,126.9,115.0,72.7,58.5,56.2,
55.1,53.5,46.6,35.4,27.5,20.1,20.0。
Embodiment 3
The synthesis of synthesis reference 2 intermediate 2 of embodiment of intermediate 4, the difference with the synthesis of intermediate 2 are only that 8-
Methyl purine replaces with equimolar uracil, obtains 4 white powder solid of intermediate, yield 49.1%, structural formula such as Fig. 3
It is shown.LC-MS (ESI, the M+H of intermediate 4+)m/z 199.3。
The synthesis of synthesis reference 2 intermediate 3 of embodiment of intermediate 5, the difference with the synthesis of intermediate 3 are only that by
Mesosome 2 replaces with equimolar intermediate 4, obtains 5 white powder solid of intermediate, yield 61.2%.The LC-MS of intermediate 5
(ESI,M-H?)m/z 169.4。
The synthesis of synthesis reference 1 compound 1 of embodiment of compound 3, the difference with the synthesis of compound 1 are only that by
Mesosome 1 replaces with equimolar intermediate 5, obtains compound 3:2- (2,4- dioxo -2H-3,4- dihydro-pyrimidin -1- base)-N-
((2S, 3R) -3- hydroxyl -4- (N- isobutyl group -4- methoxyphenyl sulphonyl amido) -1- phenyl butane -2- base)-acetamide is received
Rate 97.5%.
The synthetic route of compound 3 is shown in Fig. 4, and the analysis result of compound 3 is as follows: LC-MS (ESI, M+H+)m/z
559.71H NMR(500MHz,CDCl3) δ 8.89 (s, 1H), 7.75 (d, J=8.6Hz, 2H), 7.29-7.27 (m, 3H),
7.23-7.22 (m, 2H), 7.01 (d, J=8.6Hz, 2H), 6.70 (d, J=7.8Hz, 1H), 5.68 (d, J=7.8Hz, 1H),
4.26 (d, J=15.4Hz, 2H), 4.17 (d, J=15.7Hz, 1H), 3.99-3.98 (m, 1H), 3.90 (s, 3H), 3.13 (d, J
=5.7Hz, 2H), 2.94-2.86 (m, 4H), 1.93-1.84 (m, 1H), 0.90 (d, J=6.0Hz, 6H) .13C NMR
(101MHz,CDCl3)δ166.6,163.9,163.1,151.3,144.9,137.9,130.0,129.5,129.4,128.5,
126.5,114.4,102.6,72.3,58.3,55.7,54.1,53.0,50.4,34.7,27.0,20.1,20.0。
Embodiment 4
Anhydrous solvent n,N-Dimethylformamide (DMF) 5mL is added in 25mL eggplant-shape bottle, under stirring slowly
5 FU 5 fluorouracil (1.05g, 8.0mmol, Beijing are coupled Science and Technology Ltd.) is added, stirs evenly and is placed in ice bath, slowly
Sodium hydride (0.23g, 9.6mmol) is added portionwise, finishes to be transferred to and reacts 1h at room temperature, be slowly added dropwise into bromoacetate
(1.60g, 9.6mmol), the reaction was continued 2h.Filtering, is washed three times, merging filtrate with water (5 × 3mL), and 0.96g hydroxide is added
Sodium (24.0mmol) is stirred at room temperature reaction 1h, is placed in ice bath, adjusts pH to 3.0 with 4M HCl, stirs 30min under ice bath, quiet
It sets, filters, filter cake is washed with water, and it is dry, obtain target product white powder solid i.e. intermediate 6 (0.58g, 38.7%).It is intermediate
LC-MS (ESI, the M-H of body 6-)m/z 187.4。
The synthesis of synthesis reference 1 compound 1 of embodiment of compound 4, the difference with the synthesis of compound 1 are only that by
Mesosome 1 replaces with equimolar intermediate 6, obtains compound 4:2- (fluoro- 2,4- dioxo -2H-3, the 4- dihydro-pyrimidin -1- of 5-
Base)-N- ((2S, 3R) -3- hydroxyl -4- (N- isobutyl group -4- methoxyphenyl sulphonyl amido) -1- phenyl butane -2- base)-acetyl
Amine, yield 96.0%.
The synthetic route of compound 4 is shown in Fig. 5, and the analysis result of compound 4 is as follows: LC-MS (ESI, M+H+)m/z
577.7。1H NMR(500MHz,CDCl3) δ 10.44 (s, 1H), 8.07 (s, 1H), 7.79 (d, J=7.4Hz, 2H), 7.44-
7.38 (m, 1H), 7.33-7.24 (m, 1H), 7.15-7.14 (m, 2H), 7.06 (d, J=7.4Hz, 1H), 6.98 (d, J=
7.4Hz, 2H), 4.33 (td, J=9.4,4.8Hz, 1H), 4.29-4.20 (m, 2H), 4.16-4.13 (m, 1H), 4.01 (m,
1H),3.85(s,3H),3.29-3.26(m,1H),3.20-3.10(m,2H),2.97-2.96(m,1H),2.93-2.90(m,
2H),1.99-1.92(m,1H),0.90(brs,6H).13C NMR(101MHz,CDCl3)δ166.5,162.9,157.9,
150.0,139.1,138.0,130.0,129.5,129.4,128.4,126.4,114.4,72.3,58.1,55.7,54.1,
52.9,50.1,36.6,26.9,20.1,20.0。
Embodiment 5
Triphosgene (0.15g, 0.50mmol) is weighed in 50mL dry eggplant-shape bottle, is placed in ice bath, in nitrogen protection
Under be slowly added to 4mL anhydrous methylene chloride solvent, stirred under ice bath.By Zalcitabine (0.106g, 0.50mmol)
It is dissolved in 4mL anhydrous tetrahydro furan solvent with n,N-diisopropylethylamine (0.065g, 0.50mmol).Under condition of ice bath slowly
It is added dropwise in the dichloromethane solution for filling triphosgene, finishes, be transferred to room temperature reaction 30min.
The synthesis of intermediate b4 is similar with the synthesis of intermediate b2, and difference, which is only that, replaces with 4- Methoxybenzenesulfonyl chloride
Equimolar 4- nitrobenzene sulfonyl chloride;
The synthesis of intermediate B 1b is similar with the synthesis of B1a, and difference, which is only that, replaces with equimolar centre for intermediate b2
Body b4;
Intermediate B 1b (0.23g, 0.55mmol) is dissolved in 4mL anhydrous methylene chloride solvent, N, N- diisopropyl are added dropwise to
Base ethamine (0.071g, 0.55mmol) is stirred at room temperature reaction 5min, is then slowly added dropwise under condition of ice bath into three chloromethane of carbonic acid
Base ester, Zalcitabine reaction solution in, finish, be transferred to room temperature reaction 1h.Reaction is terminated, is added into reaction solution
10mL methylene chloride is washed (20 × 3mL) with saturated ammonium chloride solution, and organic phase is dry with anhydrous sodium sulfate, is concentrated to give crude product.
Crude product through silica gel prepare thin-layer chromatography isolated and purified (solvent be ethyl acetate, hexane and ammonium hydroxide, by volume, acetic acid
Ethyl ester: hexane: NH3·H2O=2:3:0.1%) white powder solid, that is, intermediate 7 (0.078g, 23.7%) is obtained.Intermediate 9
LC-MS(ESI,M+H+)m/z 659.6。
Intermediate 7 (0.040g, 0.06mmol) is dissolved in the in the mixed solvent of 1mL methanol and 1mL ethyl acetate, first is added
Sour ammonium (0.031g, 0.49mmol), 10%Pd/C (0.040g, humidity 36.68%), heating reflux reaction one hour, mistake while hot
Filter reaction solution, methanol washing, used after concentration prepare thin-layer chromatography isolated and purified (solvent for ethyl acetate and methanol,
By volume, ethyl acetate: methanol=4:1), it obtains white powder solid (0.035g, 91.4%), i.e. compound 5:((2S,
5R) -5- (- 1 base of 1H-2- oxo -4- aminopyrimidine)-tetrahydrofuran -2- base) ((N- is different by (2S, 3R) -3- hydroxyl -4- for methyl N -
Butyl -4- aminocarbonyl phenyl sulfoamido) -1- phenyl butane -2- base))-carbamate.
The synthetic route of compound 5 is shown in Fig. 6, and the analysis result of compound 5 is as follows: LC-MS (ESI, M+H+)m/z
629.7。1HNMR(500MHz,CDCl3) δ 9.02 (s, 1H), 7.65 (d, J=8.6Hz, 2H), 7.29-7.27 (m, 3H), 7.23-
7.22 (m, 2H), 6.61 (d, J=8.6Hz, 2H), 5.48 (d, J=7.8Hz, 1H), 5.23-5.19 (m, 1H), 4.80-4.75
(m, 1H), 4.52-4.47 (m, 2H), 4.17 (d, J=15.7Hz, 1H), 3.99-3.98 (m, 1H), 3.89 (s, 3H), 3.13
(d, J=5.7Hz, 2H), 2.99-2.84 (m, 6H), 1.93-1.84 (m, 2H), 1.71-1.68 (m, 1H), 0.93 (d, J=
6.6Hz, 3H), 0.91 (d, J=6.6Hz, 3H) .13C NMR (101MHz, MeOD) δ 169.6,168.2,164.5,158.9,
147.8,140.0,132.1,130.7,130.5,129.4,129.1,111.6,97.3,95.7,81.2,73.5,70.5,
56.2,54.0,52.4,36.3,30.2,28.1,20.6,20.5.
Embodiment 6
The synthesis of synthesis reference 1 compound 1 of embodiment of compound 6, the difference with the synthesis of compound 1 are only that by
Mesosome 1 replaces with equimolar intermediate 6, and intermediate B 1a is replaced with equimolar intermediate B 3a, obtains compound 6:N-
((2R, 3S) -3- (2- (the fluoro- 2,4- dioxo -2H-3,4- dihydro-pyrimidin -2H-1- base of 5-) acetamido) -2- hydroxyl -4- benzene
Base butyl-N- isobutyl group-P- (4- methoxyphenyl) phosphamic acid, yield 70.2%.
The synthesis process of intermediate B 3a are as follows:
4- methoxyphenyl phosphonyl dichloride (0.85g, 4.16mmol), 1-H- tetrazole (0.027g, 0.038mmol) is molten
In 8mL dry benzene, reaction flask is placed in ice bath, be successively slowly added dropwise under protection of argon gas into benzyl alcohol (0.39mL,
3.78mmol), DIEA (0.72mL, 4.16mmol).Finish, 30min be stirred to react in ice bath, be then transferred at room temperature after
Continuous reaction 2.5 hours.Reaction flask is placed in ice bath, be successively slowly added to 4 (1.27g, 3.78mmol), DIEA (0.72mL,
4.16mmol), be stirred to react 30min in ice bath, after be transferred to that the reaction was continued at room temperature 3.5 hours.Filtering is adopted after filtrate concentration
(MeOH/H is isolated and purified with reversed-phase column chromatography2O:5/1), white powder i.e. intermediate b5 (0.95g, 42.3%) is obtained, in
LC-MS (ESI, M+H+) m/z 597.7 of mesosome b5;
By intermediate b5 (0.10g, 0.17mmol), 1mL tetrahydrofuran, 0.010g 10%Pd/C, K2CO3(0.038g,
0.27mmol) and 1mL water is added in dry hydrogenation bottle, is vigorously stirred under protection of argon gas uniformly, then with hydrogen displacement 3
It is secondary, room temperature catalytic hydrogenation 4 hours under 40psi pressure.Reaction solution filtering with microporous membrane, filtrate are placed in ice bath, use
2M HCl adjusts pH to 5.0, stirs 30min, is extracted with ethyl acetate (5 × 3mL), and organic phase is dry with anhydrous sodium sulfate, dense
Contracting, obtains white powder solid i.e. intermediate b6 (0.072g, 83.9%), LC-MS (ESI, the M+H of intermediate b6+)m/z
507.7;
Referring to the synthesis of the intermediate B 1a of embodiment 1, difference, which is only that, replaces intermediate b2 for the synthesis of intermediate B 3a
For equimolar intermediate b6, intermediate B 3a, yield 54.3%, LC-MS (ESI, M+H+) m/ of intermediate B 3a are obtained
z406.7。
The synthetic route of compound 6 is shown in Fig. 7, and the analysis result of compound 6 is as follows: LC-MS (ESI, M+H+)m/z
577.7。1H NMR(500MHz,CDCl3) δ 10.21 (s, 1H), 8.04 (s, 1H), 7.75 (d, J=7.4Hz, 2H), 7.44-
7.38 (m, 1H), 7.33-7.24 (m, 2H), 7.03-6.99 (m, 2H), 6.98 (d, J=7.4Hz, 2H), 4.28 (td, J=
9.4,5.0Hz,1H),4.28-4.21(m,2H),4.19-4.15(m,1H),4.03(m,1H),3.85(s,3H),3.29-3.26
(m,1H),2.97-2.96(m,1H),2.93-2.90(m,2H),2.63-2.52(m,2H),1.95-1.87(m,1H),0.84
(d, J=6.6Hz, 3H), 0.79 (d, J=6.6Hz, 3H) .13C NMR (101MHz, CDCl3)δ168.2,163.3,157.7,
150.0,139.0,138.2,133.5,133.2,131.1,129.5,128.4,126.4,72.3,58.1,56.1,55.7,
52.9,48.5,36.2,27.1,20.1,20.0。
Embodiment 7
According to document (foundation [J] China of Dong Biao, Zhang Tian, Tao Peizhen high throughput fluorescence substrate HIV-1 Protease models
AIDS venereal disease, 2006 (05): 402-405.) method to compound 1~6 carry out HIV-1 protease inhibiting activity test:
Substrate is (Arg-Glu (EDANS)-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-Lys (DABCYL)-
Arg) (AnaSpec), substrate point of contact two sides mark Edans and Dabcyl chromophore respectively.The fluorescence hair color spectrum of Edans with
The absorption spectrum of Dabcyl is overlapped, and generates fluorescent quenching by fluorescence resonance energy transfer in distance close enough, is made complete
Substrate almost without fluorescence.When fluorogenic substrate is after hiv protease is cut, Edans chromophore is far from Dabcyl group, fluorescence
Quenched conditions disappear, and at this moment Edans just generates fluorescence under the exciting light of 340nm at 490nm, after untested compound is added,
Then substrate product is reduced when compound is strong to enzyme inhibition activity, and fluorescence intensity reduces, otherwise fluorescence intensity increases.
According to document (foundation [J] China of Dong Biao, Zhang Tian, Tao Peizhen high throughput fluorescence substrate HIV-1 Protease models
AIDS venereal disease, 2006 (05): 402-405) method the measurement of HIV-1PR inhibitory activity is carried out to sample with 96 orifice plates, often
Substrate (5 μM) and 185 μ L of buffer is added in hole, and 5 μ L sample solution are added, and measurement blank absorbs, 10 μ L HIV-1PR are added, incubate
The absorbance for measuring 490nm wavelength after 5min is educated, the inhibiting rate of sample under each concentration is calculated, is calculated with Graphpad software
Obtain IC50Value is the positive with DRV (Darunavir) (being purchased from U.S. ARP (American Research Product) company)
Control.
Wherein, HIV-1PR is according to (expression, purifying and its inhibitor in-vitro screening side of the .HIV-1 protease such as Wang Yunhua
Method establishes CHINA virus March phase .2006 of volume 21 2) in method in expression in escherichia coli and purify, HIV-1PR
Use PD-10 column desalination.
With HIV-1 protease inhibitors DRV (Darunavir) be positive control, according to the method described above measure embodiment 1~
1~6 pair of protease (PR) inhibitory activity of compound and cytotoxicity prepared by 6.The result shows that compound 2, compound 5 and change
It closes object 6 and positive control medicine HIV-1 protease inhibitors DRV is better than to the inhibitory activity of HIV-1 protease;Compound 1, chemical combination
Object 3 and compound 4 are living to the inhibitory activity of HIV-1 protease and the inhibition of positive control medicine HIV-1 protease inhibitors DRV
Property it is close or quite (table 1).
The inhibitory activity of 1 1~6 pair of HIV-1 protease of compound of table
Compound | PRIC50(nM) |
|
2.11±0.37 |
|
0.94±0.32 |
Compound 3 | 2.53±0.42 |
Compound 4 | 1.95±0.32 |
Compound 5 | 0.46±0.22 |
Compound 6 | 0.032±0.019 |
DRV | 1.12±0.59 |
The test method of cytotoxicity:
Compound Cytotoxicity is measured using kit Cell Counting Kit-8 (CCK-8 kit).With 96 orifice plates
Cytotoxicity test is carried out to sample, every hole is added 20,000,293T cell, and 1 μ L sample is added in incubation afterwards for 24 hours, continues to be incubated for
For 24 hours, be added 10 μ L CCK-8,2h after with measure absorbance under 450nm, calculate the percentage of each concentration survivaling cell, use
CC is calculated in Graphpad software50Value, using DMSO as blank control, with DRV (Darunavir) for positive control.
The cytotoxicity of 2 compound 1~6 of table
The result shows that above compound 1~6 all has lower cytotoxicity (table 2).
Embodiment 8
Using 293T cell as virus host, measurement sample inhibits pseudotype virus reporter gene uciferase activity.It adopts
With envelope glycoprotein pHCMV-G (VSV-G) the cotransfection 293T of pNL-Luc-E- Strain and expression vesicular stomatitis virus
Generate VSV-G-HIV.
According to document, [Wang Ping, Chen Huan, Luo Ronghua wait .VSVG/HIV-1NL4-3Luc pseudovirus screens anti-HIV-1 medicines
Condition optimizing and apply [J] Chinese Pharmacological Bulletin, 2016,32 (3): 433-438.] method carry out the suppression of HIV-1 protease
The test of rate processed:
Envelope glycoprotein pHCMV-G (VSV-G) plasmid of plasmid pNL-Luc-E- and expression vesicular stomatitis virus is total
It transfects 293T cell and prepares VSV-G-HIV pseudovirus, a certain concentration protease inhibitor sample is added after transfecting 5h, sets 5%
CO2, 37C culture 48 hours.Every hole takes 10 μ l inoculation 293T cell of supernatant, 96 well culture plate later, after culture 48 hours,
Uciferase activity in infection cell is measured, the inhibiting rate of each sample is calculated.
With HIV-1 protease inhibitors DRV (Darunavir) for positive control, according to the method described above under 10nM concentration
Determine the inhibiting rate of 1~6 pair of hiv protease (PR) of above compound.The result shows that above-mentioned 6 compounds all have it is higher
Inhibiting rate, wherein compound 5 and 6 inhibiting rate of compound (table 3) are higher than positive control.As shown in table 3.
The inhibiting rate of 3 1~6 pair of HIV-1 protease of compound of table
Embodiment 9
The test method of HIV-1 reverse transcriptase inhibitory activity is as follows:
Primer is 5 '-CAG CAG TACAAATGG CAG TATTC-3 ', is marked in the position T19 with Cyanine 5 (Cy5)
Note, with 3 '-TGT CGT CAT GTT TAC CGT CATAAG TAGGTG TTACTAGTC CGATTT CCC CTAGTC
CGACCCATG-5 ' is template, is marked in the position T2 with carboxytetramethylrhodamine (TMR), TMR excitation wavelength
For 540nm, launch wavelength 580nm, using FRET as donor.The measurement of HIV-1RT inhibitory activity is carried out to sample with 96 orifice plates,
100nM HIV-1RT is mixed with the bis- index object/template composites of 100nM, and kinetics of polymerization reaction is opened by 100 μM of dNTPs are added
It is dynamic.HIV-1RT and double index object/templates is added, the absorbance of 580nm wavelength is measured after incubation 5min, calculates each concentration
IC is calculated with Graphpad software in the inhibiting rate of lower sample50Value, with EFV (Efavirenz) for positive control.If without spy
Different explanation, all tests are carried out in buffer at 20 DEG C.Buffer 4M hydrochloric acid (pH7.5), 10mM KCl and 6mM
MgCl configuration.
With HIV-1 reverse transcriptase inhibitor EFV (Efavirenz) for positive control, determined under 10nM concentration above-mentioned
The inhibiting rate of 1~6 pair of hiv reverse transcriptase (RT) of compound.The result shows that above-mentioned 6 compounds all have higher inhibiting rate,
Wherein compound 5 and 6 inhibiting rate of compound (table 4) are suitable with positive control inhibiting rate.As shown in table 4.
The inhibiting rate of 4 1~6 pair of HIV-1 reverse transcriptase of compound of table
As seen from the above embodiment, the present invention provides a kind of nucleic acid base compound or its pharmaceutically acceptable salt,
The compound or its pharmaceutically acceptable salt have the apparent activity for inhibiting hiv protease and/or reverse transcriptase;Toxicity is ground
Study carefully and shows that it, with good druggability, shows that such compound has a good application prospect as anti-AIDS drug.Root
According to the experimental data of embodiment it is found that the compound of the present invention has inhibition to live in HIV-1 protease and HIV-1 reverse transcriptase
Property (table 1), and all have lower cytotoxicity (table 2).Nucleic acid base compound of the invention or its is pharmaceutically acceptable
Salt be expected to become while inhibiting double target spot inhibitor of hiv protease and reverse transcriptase.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also answered
It is considered as protection scope of the present invention.
Claims (10)
1. a kind of nucleic acid base compound or its pharmaceutically acceptable salt have structure shown in Formulas I:
In Formulas I, R1For amino, methoxyl group, nitro, aminomethyl or methylol;
X is-CH2,-O- ,-S- or-NH-;
When X is-CH2When, R Ra, Rb or Rc;
When X is-O- ,-S- or-NH-, R Rc;
Wherein, R2For hydrogen, hydroxyl, amino or halogen;R3For hydrogen, hydroxyl, amino, halogen or methyl;R4For hydrogen or methyl;R5For
Hydrogen, hydroxyl, amino or phosphate group;
When Z is nitrogen, R6For hydrogen, hydroxyl, amino or phosphate group;When Z is oxygen or sulphur, R6It is not present.
2. nucleic acid base compound according to claim 1 or its pharmaceutically acceptable salt, which is characterized in that the core
Soda acid based compound includes 2- (the chloro- 9H- purine -9- base of 6-)-N- ((2S, 3R) -3- hydroxyl -4- (N- isobutyl group -4- methoxyl group
PhenylSulphon amido) -1- phenyl butane -2- base)-acetamide, 2- (8- methyl -9H- purine -9- base)-N- [(2S, 3R) -3- hydroxyl
Base -4- (N- isobutyl group -4- methoxyphenyl sulphoxide imine base) -1- phenyl butyl -2- base]-acetamide, 2- (2,4- dioxo -
2H-3,4- dihydro-pyrimidin -1- base)-N- ((2S, 3R) -3- hydroxyl -4- (N- isobutyl group -4- methoxyphenyl sulphonyl amido) -1-
Phenyl butane -2- base)-acetamide, 2- (the fluoro- 2,4- dioxo -2H-3,4- dihydro-pyrimidin -1- base of 5-)-N- ((2S, 3R) -3-
Hydroxyl -4- (N- isobutyl group -4- methoxyphenyl sulphonyl amido) -1- phenyl butane -2- base)-acetamide, ((2S, 5R) -5-
(- 1 base of 1H-2- oxo -4- aminopyrimidine)-tetrahydrofuran -2- base) methyl N-((2S, 3R) -3- hydroxyl -4- (N- isobutyl group -4-
Aminocarbonyl phenyl sulfoamido) -1- phenyl butane -2- base))-carbamate or N- ((2R, 3S) -3- (2- (fluoro- 2,4- bis- of 5-
Oxo -2H-3,4- dihydro-pyrimidin -2H-1- base) acetamido) -2- hydroxy-4-phenyl butyl-N- isobutyl group-P- (4- methoxyl group
Phenyl) phosphamic acid.
3. the preparation method of nucleic acid base compound of any of claims 1 or 2, comprising the following steps:
X is-CH in the compound of the structure shown in the Formulas I2, R be Ra or Rb when, by with structure shown in Formula II -1 compound with
Amine derivative carries out condensation reaction under the action of catalyst, obtains the compound with structure shown in Formulas I;
In Formula II -1, R is Ra or Rb, and the Ra isThe Rb isWherein, R2For
Hydrogen, hydroxyl, amino or halogen;R3For hydrogen, hydroxyl, amino, halogen or methyl;R4For hydrogen or methyl;
X is-CH in the compound of the structure shown in the Formulas I2,-O-,-S- or-NH-, R be when being Rc, will have structure shown in Formula II -2
Compound, carbonic acid trichloromethyl ester and amine derivative carry out condensation reaction under the action of catalyst, obtain with shown in Formulas I tie
The compound of structure;
Formula II -2 R-XH,
In Formula II -2, X is-CH2,-O- ,-S- or-NH-;R is Rc, and the Rc isWherein, R2For hydrogen, hydroxyl,
Amino or halogen, R3For hydrogen, hydroxyl, amino, halogen or methyl;R4For hydrogen or methyl;R5For hydrogen, hydroxyl, amino or phosphate
Group;When Z is nitrogen, R6For hydrogen, hydroxyl, amino or phosphate group;When Z is oxygen or sulphur, R6It is not any atom or group;
The amine derivative has structure shown in formula III:
4. preparation method according to claim 3, which is characterized in that the compound with structure shown in Formula II -1 with
Amine derivative is condensed under the catalytic action of carbodiimide hydrochloride, I-hydroxybenzotriazole and 4-dimethylaminopyridine
Reaction;
The compound and carbonic acid trichloromethyl ester and amine derivative with structure shown in Formula II -2 is in N, N- diisopropyl second
Condensation reaction is carried out under the catalytic action of amine.
5. preparation method according to claim 3, which is characterized in that the compound with structure shown in Formula II -1
Preparation method, comprising the following steps:
Substituted pyrimidines base or substituted purin base and bromoacetic acid or bromoacetate are subjected to substitution reaction, obtain replacing production
Object;
The substitution product is hydrolyzed, the compound with structure shown in Formula II -1 is obtained;
The substituted pyrimidines base has structure shown in formula a:
The substituted purin base has structure shown in formula b:
6. preparation method according to claim 3, which is characterized in that when Y is in the amine derivativeWhen, it is described
Amine derivative has structure shown in formula III -1:
The preparation method of the amine derivative with structure shown in formula III -1, comprising the following steps:
[(S) -1- ((S)-ethylene oxide -2- base) -2- benzene ethylamino t-butyl formate] and isobutyl amine progress nucleophilic displacement of fluorine is anti-
It answers, obtains (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate;
The R of (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate by described in and structure shown in formula d1Replace
Benzene sulfonyl chloride carries out nucleophilic substitution, obtains the intermediate of structure shown in formula c;
By the intermediate Deprotection of structure shown in the formula c, the amine derivative with structure shown in formula III -1 is obtained;
7. preparation method according to claim 3, which is characterized in that when Y is in the amine derivativeWhen, institute
Amine derivative is stated with structure shown in formula III -2:
The preparation method of the amine derivative with structure shown in formula III -2, comprising the following steps:
[(S) -1- ((S)-ethylene oxide -2- base) -2- benzene ethylamino t-butyl formate] and isobutyl amine progress nucleophilic displacement of fluorine is anti-
It answers, obtains (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate;
The R of (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate by described in and structure shown in formula d1Replace
Benzene sulfonyl chloride carries out nucleophilic substitution, obtains the intermediate of structure shown in formula c;
The intermediate of structure shown in the formula c and Sodium azide are subjected to imidization, obtain the intermediate of structure shown in formula e;
By the intermediate Deprotection of structure shown in the formula e, the amine derivative with structure shown in formula III -2 is obtained.
8. preparation method according to claim 3, which is characterized in that when Y is in the amine derivativeWhen, institute
Amine derivative is stated with structure shown in formula III -3:
The preparation method of the amine derivative with structure shown in formula III -3, comprising the following steps:
[(S) -1- ((S)-ethylene oxide -2- base) -2- benzene ethylamino t-butyl formate] and isobutyl amine progress nucleophilic displacement of fluorine is anti-
It answers, obtains (1S, 2R) -1- benzyl -2- hydroxyl -3- (isobutyl amine) t-butyl carbamate;
By 4- substituted-phenyl phosphonyl dichloride, benzyl alcohol and (1S, the 2R) -1- benzyl -2- hydroxyl-with structure shown in formula f
3- (isobutyl amine) t-butyl carbamate carries out Arbuzov and reacts to obtain the intermediate of structure shown in formula g;
By the intermediate and H of structure shown in the formula g2Reduction reaction is carried out, the intermediate of structure shown in formula h is obtained;
By the intermediate Deprotection of structure shown in the formula h, the amine derivative with structure shown in formula III -3 is obtained.
9. nucleic acid base compound as claimed in claim 1 or 2 or its pharmaceutically acceptable salt are preparing answering in hiv inhibitor
With the hiv inhibitor is using hiv protease and reverse transcriptase as target spot.
10. application according to claim 9, which is characterized in that the nucleic acid base compound or its is pharmaceutically acceptable
Dosage of the salt in hiv inhibitor be 0.01~100nM.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810493926.7A CN108558883B (en) | 2018-05-22 | 2018-05-22 | A kind of nucleic acid base compound or its pharmaceutically acceptable salt and its preparation method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810493926.7A CN108558883B (en) | 2018-05-22 | 2018-05-22 | A kind of nucleic acid base compound or its pharmaceutically acceptable salt and its preparation method and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108558883A CN108558883A (en) | 2018-09-21 |
CN108558883B true CN108558883B (en) | 2019-10-15 |
Family
ID=63539595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810493926.7A Active CN108558883B (en) | 2018-05-22 | 2018-05-22 | A kind of nucleic acid base compound or its pharmaceutically acceptable salt and its preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108558883B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113277991B (en) * | 2021-02-03 | 2022-07-12 | 中国医学科学院医药生物技术研究所 | Nitrogen heterocyclic ring amino derivative, preparation method thereof and anti-HIV-1 drug |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8193227B2 (en) * | 2003-12-11 | 2012-06-05 | Abbott Laboratories | HIV protease inhibiting compounds |
CN101062909A (en) * | 2006-04-28 | 2007-10-31 | 北京大学 | HIV-1prolease peptide mimic new inhibitor having biological activity, preparation method and usage |
US20180085387A1 (en) * | 2016-09-27 | 2018-03-29 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
-
2018
- 2018-05-22 CN CN201810493926.7A patent/CN108558883B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN108558883A (en) | 2018-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CZ291054B6 (en) | Pharmaceutical compositions comprising protease inhibitors, i.e. sulfonamides containing tetrahydrofuran ring | |
US20040039016A1 (en) | HIV protease inhibitors | |
NZ500592A (en) | 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors | |
SK143097A3 (en) | Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease | |
Liu et al. | Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization | |
DE60132177T2 (en) | AMINO ACID DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | |
CN101367749A (en) | A set of mesidino mesitoyl derivant, preparation and application thereof | |
CN112920208B (en) | Boric acid-containing indole aryl sulfone derivative and preparation method and application thereof | |
CN112592331B (en) | Oseltamivir PROTAC compound, preparation method thereof and application thereof in anti-influenza virus drugs | |
CN112028836B (en) | Diarylpyrimidine derivative containing six-membered nitrogen heterocycle and preparation method and application thereof | |
CN107936022A (en) | Xanthine LSD1 inhibitor and its preparation method and application | |
CN108558883B (en) | A kind of nucleic acid base compound or its pharmaceutically acceptable salt and its preparation method and application | |
CN108558808B (en) | Amide derivative or pharmaceutically acceptable salt thereof, and preparation method and application thereof | |
CN111675661B (en) | Diaryl pyrimidine HIV-1 reverse transcriptase inhibitor containing trans double bond and preparation method and application thereof | |
CN109369623B (en) | Substituted 1,2,3 triazole diaryl pyrimidine derivative and preparation method and application thereof | |
CN112898193B (en) | Indole aryl sulfone derivative and preparation method and application thereof | |
US10266489B2 (en) | Pyrrolic amide compound and preparation method and application thereof | |
CN111205206B (en) | Carbonyl compound containing amino acid connecting chain or pharmaceutically acceptable salt thereof, and preparation method and application thereof | |
CN108440500B (en) | Quinazoline HIV-1 inhibitor and preparation method and application thereof | |
CN109836477B (en) | Phenylalanine derivative containing benzothiadiazine-3-ketone 1, 1-dioxide and preparation method and application thereof | |
CN108409698A (en) | Bis- target spot hiv inhibitors of RT/PR and its preparation method and application | |
JP2022551557A (en) | N-(2-aminophenyl)-prop-2-enamide derivatives and their use in treating cancer | |
CN114230630B (en) | Triptolide derivative and application thereof | |
CN112961081B (en) | Bibenzamide urea compound and preparation method and application thereof | |
CN105985335B (en) | Hydroxamic acid compound, preparation method and its usage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |